HC Wainwright & Co. Reiterates Buy on Arcturus Therapeutics, Maintains $51 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Ed Arce reiterated a Buy rating on Arcturus Therapeutics (NASDAQ:ARCT) and maintained a $51 price target.
June 01, 2023 | 3:40 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Arcturus Therapeutics (ARCT) received a reiterated Buy rating and a maintained $51 price target from HC Wainwright & Co. analyst Ed Arce.
The reiterated Buy rating and maintained $51 price target by HC Wainwright & Co. analyst Ed Arce indicates a positive outlook for Arcturus Therapeutics. This news is likely to have a positive short-term impact on the stock price as it shows continued confidence in the company's potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100